Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;99(5):1308-1324.
doi: 10.1002/jnr.24805. Epub 2021 Feb 26.

Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach

Ming-Ming Xu  1 , Mao-Tian Zhou  2 , Shu-Wei Li  3 , Xue-Chu Zhen  4 , Shuang Yang  1
Affiliations
Review

Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach

Ming-Ming Xu et al. J Neurosci Res. 2021 May.

Abstract

Neurodegenerative diseases (NDs) are incurable and can develop progressively debilitating disorders, including dementia and ataxias. Alzheimer's disease and Parkinson's disease are the most common NDs that mainly affect the elderly people. There is an urgent need to develop new diagnostic tools so that patients can be accurately stratified at an early stage. As a common post-translational modification, protein glycosylation plays a key role in physiological and pathological processes. The abnormal changes in glycosylation are associated with the altered biological pathways in NDs. The pathogenesis-related proteins, like amyloid-β and microtubule-associated protein tau, have altered glycosylation. Importantly, specific glycosylation changes in cerebrospinal fluid, blood and urine are valuable for revealing neurodegeneration in the early stages. This review describes the emerging biomarkers based on glycoproteomics in NDs, highlighting the potential applications of glycoprotein biomarkers in the early detection of diseases, monitoring of the disease progression, and measurement of the therapeutic responses. The mass spectrometry-based strategies for characterizing glycoprotein biomarkers are also introduced.

Keywords: Alzheimer's disease; Parkinson's disease; biomarkers; glycoproteomics; glycosylation; mass spectrometry; neurodegenerative diseases.

PubMed Disclaimer

References

REFERENCES

    1. Abdelhak, A., Hottenrott, T., Morenas-Rodríguez, E., Suárez-Calvet, M., Zettl, U. K., Haass, C., Meuth, S. G., Rauer, S., Otto, M., Tumani, H., & Huss, A. (2019). Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: Potential of serum GFAP as disease severity marker? Frontiers in Neurology, 10, 280. https://doi.org/10.3389/fneur.2019.00280
    1. Akasaka-Manya, K., Kawamura, M., Tsumoto, H., Saito, Y., Tachida, Y., Kitazume, S., & Endo, T. (2017). Excess APP O-glycosylation by GalNAc-T6 decreases Abeta production. Journal of Biochemistry, 161(1), 99-111.
    1. Akasaka-Manya, K., Manya, H., Sakurai, Y., Wojczyk, B. S., Kozutsumi, Y., Saito, Y., & Endo, T. (2010). Protective effect of N-glycan bisecting GlcNAc residues on beta-amyloid production in Alzheimer's disease. Glycobiology, 20(1), 99-106.
    1. Albrecht, S., Unwin, L., Muniyappa, M., & Rudd, P. M. (2014). Glycosylation as a marker for inflammatory arthritis. Cancer Biomarkers, 14(1), 17-28. https://doi.org/10.3233/CBM-130373
    1. Almkvist, O., Darreh-Shori, T., Stefanova, E., Spiegel, R., & Nordberg, A. (2004). Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. European Journal of Neurology, 11(4), 253-261. https://doi.org/10.1046/j.1468-1331.2003.00757.x

LinkOut - more resources